News - Neurological

Filter

Current filters:

Neurological

Popular Filters

82 to 106 of 917 results

FDA recommends high-dose acetaminophen combo drugs be discontinued

FDA recommends high-dose acetaminophen combo drugs be discontinued

16-01-2014

The US Food and Drug Administration is recommending health care professionals discontinue prescribing…

NeurologicalNorth AmericaPharmaceuticalRegulationUSA

Jazz Pharma in $397 million deal with Aerial for narcolepsy drug ADX-NO5

14-01-2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals has inked an agreement with the USA’s Aerial BioPharma…

ADX-NO5Aerial BioPharmaGlobalJazz PharmaceuticalsLicensingNeurologicalPharmaceutical

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

13-01-2014

Based on positive Phase II data, US drug major Eli Lilly has acquired all development rights for a calcitonin…

Arteaus TherapeuticsEli LillyLicensingLY2951742NeurologicalPharmaceutical

NovaSAID partners with Cadila to develop inflammation and pain therapies

10-01-2014

Swedish research based company NovaSAID (a Karolinska Development portfolio firm) and Cadila Pharmaceuticals,…

Cadila PharmaceuticalsInflammatory diseasesNeurologicalNovaSAIDPharmaceuticalResearch

InteRNA Technologies, UCB and University of Bonn to collaborate on MicroRNAs in neurodegenerative disease

10-01-2014

Dutch pharma company InteRNA Technologies has entered into a collaboration with the Neuroallianz Consortium,…

NeurologicalNorthern EuropePharmaceuticalResearch

Adamas Pharma earns $40 milestone in Forest deal

10-01-2014

California, USA-based Adamas Pharmaceuticals revealed yesterday (January 9) that it has received $40…

Adamas PharmaceuticalsdonepezilFinancialForest LaboratoriesMDX-8704NamendaNeurologicalPharmaceuticalResearch

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

08-01-2014

In yet another negative opinion from the German Institute for Quality and Efficiency in Health Care (IQWiG)…

AubagioGermanyNeurologicalNorthern EuropePharmaceuticalPricingRegulationSanofi

Neurocrine rockets on positive Phase II data for tardive dyskinesia treatment

08-01-2014

Shares of Neurocrine Biosciences were up almost 80% yesterday after it announced that NBI-98854, a small…

BiotechnologyNeurocrine BiosciencesNeurologicalResearchUSA

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Impax and DURECT in $63 million deal for Eladur pain patch

07-01-2014

US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

Ossianix in CNS research deal with Lundbeck

Ossianix in CNS research deal with Lundbeck

07-01-2014

Privately-held US firm Ossianix has announced a strategic research collaboration with Danish central…

LundbeckNeurologicalOssianixPharmaceuticalResearch

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

moksha8 files Viibryd and Colobreathe in Brazil; amends Forest alliance

06-01-2014

Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA,…

BrazilColoBreatheForest LaboratoriesLicensingMerck SeronoMoksha8NeurologicalPharmaceuticalRare diseasesRegulationSouth AmericaViibryd

AstraZeneca inks neuroscience collaboration with Lieber Institute

AstraZeneca inks neuroscience collaboration with Lieber Institute

04-01-2014

Anglo-Swedish drug major AstraZeneca has entered into a two-year research collaboration with the USA-based…

AstraZenecaNeurologicalPharmaceuticalResearch

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

US FDA calls for more trials on Genzyme’s Lemtrada

US FDA calls for more trials on Genzyme’s Lemtrada

30-12-2013

There was a significant disappointment this morning for French drug major Sanofi, when it revealed that…

BayerGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofiUSA

New schizophrenia drug Abilify to lead the market by 2016

New schizophrenia drug Abilify to lead the market by 2016

29-12-2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia…

AbilifyAbilify MaintenaFinancialGlobalLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Lundbeck’s Brintellix OKed in Europe for adults with depression

Lundbeck’s Brintellix OKed in Europe for adults with depression

29-12-2013

The European Commission has granted marketing authorization for Danish CNS specialist Lundbeck’s Brintellix…

BrintellixLundbeckNeurologicalPharmaceuticalRegulation

Report: Alzheimer’s Disease market to reach $3.8 billion in 2019

Report: Alzheimer’s Disease market to reach $3.8 billion in 2019

27-12-2013

The Alzheimer’s Disease (AD) market will increase slightly from $3.6 billion in 2012 to $3.8 billion…

FinancialGlobalMarkets & MarketingNeurologicalPharmaceuticalResearch

Orion licenses Janssen to develop novel treatment for Alzheimer's disease

Orion licenses Janssen to develop novel treatment for Alzheimer's disease

20-12-2013

Orion Corp has entered into a license agreement with Janssen Pharmaceuticals for the development and…

FinlandJanssenLicensingNeurologicalNorthern EuropeOrion CorpPharmaceutical

Forest debuts MMD drug Fetzima in US pharmacies

19-12-2013

US drugmaker Forest Laboratories says that Fetzima (levomilnacipran ER capsules) is now available in…

FetzimaForest LaboratoriesMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPierre FabreUSA

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Targacept to drop development of TC-5619 in schizophrenia, after disappointing trial results

17-12-2013

Shares of US biopharma drug developer Targacept tanked nearly 33% to $4 in pre-market trading on December…

NeurologicalPharmaceuticalResearchTargaceptTC-5619

82 to 106 of 917 results

Company Spotlight

Fibrotech

Fibrotech

Back to top